Archon X Prize
| Archon Genomics X PRIZE presented by Express Scripts | |
|---|---|
 |
|
| Awarded for | "build a device and use it to sequence 100 human genomes within 30 days or less, with an accuracy of no more than one error in every 1,000,000 bases sequenced, with sequences accurately covering at least 98% of the genome, and at a recurring cost of no more than US$1,000 per genome"[1] |
| Country | Worldwide |
| Presented by | X PRIZE Foundation |
| Reward | US$10 million[1] |
| Official website | genomics.xprize.org |
The Archon Genomics X PRIZE presented by Express Scripts for Genomics, the second X Prize to be offered by the X Prize Foundation, based in Playa Vista, California, was announced on October 4, 2006. The Archon X Prize in genomics began as a joint effort of the X Prize Foundation and the J. Craig Venter Science Foundation. [2][3][4] The J. Craig Venter Science Foundation offered the $500,000 (US) Innovation in Genomics Science and Technology Prize in September 2003 aimed at stimulating development of less expensive and faster sequencing technology. To attract even more resources to this goal, Dr. Venter joined forces with the X Prize Foundation, wrapping his competition and prize purse into its current incarnation, The Archon Genomics X Prize presented by Express Scripts.
Overview [edit]
The US$10 million prize is to be awarded to "the first Team that can build a whole human genome sequencing device and use it to sequence 100 human genomes within 30 days or less, with an accuracy of no more than one error in every 1,000,000 bases sequenced, with an accuracy rate of at least 98% of the genome, and at a recurring cost of no more than $1,000 (US) per genome." The $10 million was donated by Canadian geologist and philanthropist Stewart Blusson, who co-discovered the Ekati Diamond Mine. The name "Archon" is the name of Blusson's company, which refers to the type of lithosphere beneath northern Canada.
The 100 human genomes to be sequenced in this competition will be donated by 100 centenarians (ages 100 or older) from all over the world, known as the 100 Over 100. Sequencing the genomes of the 100 Over 100 presents an unprecedented opportunity to identify those "rare genes" that protect against diseases, while giving researchers valuable clues to health and longevity. These centenarians’ genes are providing us with a window to the past that will significantly impact the future of healthcare.
The result will be the world's first "medical grade” genome, a critically needed clinical standard that will transform genomic research into usable medical information to improve patient diagnosis and treatment. This global competition will inspire breakthrough genome sequencing innovations and technologies that will usher in a new era of personalized medicine.
References [edit]
- ^ a b "PRIZE Overview".
- ^ Kedes, L.; Campany, G. (2011). "The new date, new format, new goals and new sponsor of the Archon Genomics X PRIZE Competition". Nature Genetics 43 (11): 1055–1058. doi:10.1038/ng.988. PMID 22030612.
- ^ Kedes, L.; Liu, E.; Jongeneel, C. V.; Sutton, G. (2011). "Judging the Archon Genomics X PRIZE for whole human genome sequencing". Nature Genetics 43 (3): 175. doi:10.1038/ng0311-175. PMID 21350493.
- ^ Kedes, L.; Liu, E. T. (2010). "The Archon Genomics X PRIZE for whole human genome sequencing". Nature Genetics 42 (11): 917–918. doi:10.1038/ng1110-917. PMID 20980980.
|
|||||||||||
